FDC Limited Faces Fifth Ophthalmic Recall: Ciprofloxacin Solution Impacted by Recurring Container Defects
FDC Limited has initiated a Class II recall (D-0282-2025) for 90,960 bottles of Ciprofloxacin Ophthalmic Solution USP, 0.3%, due to defective containers. This marks the fifth ophthalmic product recall for FDC Limited since May 2024, signaling persistent quality control issues at its Aurangabad, India facility and posing significant supply chain risks for U.S. distributors like Leading Pharma LLC.
FDA Class II Recall: FDC Limited's Ciprofloxacin Ophthalmic Solution Impacted by Container Defect
FDC Limited, a prominent pharmaceutical manufacturer based in Aurangabad, Maharashtra State, India, has initiated a voluntary Class II recall, identified as D-0282-2025, for its Ciprofloxacin Ophthalmic Solution USP, 0.3%. This critical ophthalmic antibiotic, distributed nationwide in the U.S. by Leading Pharma LLC of Fairfield, NJ, is being pulled from the market due to a significant container defect. Specifically, the cap's spike has been found lodged in the nozzle of the product bottle, rendering the solution inaccessible to patients. The recall impacts 90,960 bottles from Lot 084A067, with an expiration date of December 31, 2025. The recall was initiated on March 11, 2025, with the FDA classifying it on March 17, 2025. For procurement directors, this event necessitates an immediate assessment of existing inventory for NDC 69315-308-05 and a rapid search for alternative supply to prevent patient care disruptions. Regulatory affairs teams must monitor FDC Limited's response and corrective actions closely, as this is not an isolated incident.
FDC Limited's Aurangabad Facility: A Critical Node with Persistent Quality Challenges
The manufacturing facility located at B-8 MIDC Industrial Area, Waluj District, Aurangabad, Maharashtra State, India, is central to FDC Limited’s supply of ophthalmic products to the U.S. market. This site is responsible for producing the Ciprofloxacin Ophthalmic Solution USP, 0.3% now under recall. The repeated nature of container defects originating from this specific location suggests a systemic quality control issue within the facility's manufacturing processes or its component sourcing for packaging. For supply chain VPs, the reliability of this facility as a source for critical medications, including Ciprofloxacin, is now significantly compromised. The ongoing status of the recall indicates that the issue is still being managed, and the full extent of the impact on future supply from this facility remains to be determined. Business development executives should note that sustained issues at key manufacturing sites like Aurangabad can undermine long-term supply agreements and necessitate strategic shifts in supplier portfolios.
Supply Chain Exposure: Nationwide U.S. Impact for Ciprofloxacin Ophthalmic Solution
The recalled Ciprofloxacin Ophthalmic Solution USP, 0.3% was distributed nationwide across the United States, primarily through Leading Pharma LLC. This broad distribution pattern means that pharmacies, hospitals, and ultimately patients across the country are directly affected by the unavailability of 90,960 bottles of this essential human prescription drug. Ciprofloxacin is a widely used broad-spectrum antibiotic for bacterial eye infections, making its sudden withdrawal a concern for patient access. Procurement teams at distributors and large healthcare systems must immediately identify their exposure to Lot 084A067 and initiate contingency plans. Regulatory affairs heads should anticipate increased inquiries from healthcare providers and consumers regarding product availability and safety. The commercial implications extend beyond the immediate recall, potentially impacting Leading Pharma LLC’s ability to reliably supply this product and potentially damaging brand trust if alternative solutions are not swiftly secured.
FDC Limited's Escalating Regulatory History: A Pattern of Recurring Container Defects
This latest recall of Ciprofloxacin Ophthalmic Solution marks the fifth instance of FDC Limited facing regulatory action due to container defects in its ophthalmic products within a year. The company's history reveals a concerning pattern: on May 15, 2024, August 28, 2024, and November 13, 2024, FDC Limited initiated recalls for Timolol Maleate Ophthalmic Solution, each citing container defects. Furthermore, on January 15, 2025, another Ciprofloxacin Ophthalmic Solution recall was initiated due to recurring container defects. This consistent recurrence across different ophthalmic molecules strongly suggests a systemic, unresolved issue in FDC Limited's manufacturing or packaging processes, rather than isolated incidents. For procurement directors, this history elevates FDC Limited to a high-risk supplier for ophthalmic products, demanding immediate re-evaluation of all contracts and a proactive search for more reliable manufacturers. Regulatory affairs heads should anticipate heightened scrutiny from the FDA on FDC Limited's overall quality management system, potentially leading to more severe enforcement actions if this pattern persists.
Remediation and Future Outlook: Mitigating Recurrence Risks and FDA Scrutiny
As a voluntary, firm-initiated Class II recall, FDC Limited is responsible for identifying the root cause of the defective container issue and implementing comprehensive corrective and preventive actions (CAPA). Given the recurring nature of these defects across multiple ophthalmic products, the FDA will undoubtedly expect a robust and systemic remediation plan that addresses underlying manufacturing or quality control deficiencies at the Aurangabad facility. Failure to adequately resolve these persistent issues could lead to escalated regulatory actions, including FDA Warning Letters, increased inspections with Form 483 observations, or even Import Alerts, which would severely restrict FDC Limited's ability to supply the U.S. market. Supply chain VPs must demand detailed CAPA reports and evidence of their effectiveness from FDC Limited. Business development executives should assess the long-term viability of FDC Limited as a partner, considering the potential for ongoing supply disruptions and reputational damage. Proactive engagement with alternative suppliers for Ciprofloxacin and other ophthalmic generics is now a critical imperative to safeguard supply continuity and patient access.